antibiot
resist
rise
danger
high
level
worldwid
oral
respiratori
tract
infect
caus
bacteria
streptococcu
pneumonia
klebsiella
pneumonia
pose
particular
threat
rise
antibioticresist
strain
vulner
patient
popul
high
risk
infect
season
endem
virus
influenza
anoth
signific
caus
respiratori
infect
worldwid
annual
influenza
epidem
estim
result
million
case
sever
ill
death
addit
season
endem
virus
emerg
reemerg
viru
outbreak
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
coronavirus
sarscov
merscov
requir
close
contact
humantohuman
transmiss
spread
nosocomi
unlik
remain
four
coronavirus
typic
associ
mild
selflimit
respiratori
ill
sarscov
merscov
caus
sever
respiratori
symptom
associ
consider
mortal
vaccin
specif
antivir
treatment
avail
sarscov
merscov
outbreak
howev
quickli
effect
control
prevent
strategi
base
upon
earli
accur
viral
diagnosi
knowledg
current
epidemiolog
season
effect
hygien
practic
decreas
risk
transmiss
effect
hand
hygien
minimis
transmiss
pathogen
contamin
hand
infect
individu
either
direct
persontoperson
contact
indirectli
via
contamin
surfac
respiratori
pathogen
influenza
also
transmit
via
airborn
dispers
small
particl
aerosol
b
lm
infect
individu
breath
cough
sneez
respiratori
syncyti
virus
sarscov
merscov
spread
larg
droplet
propel
air
inocul
eye
nose
mouth
close
rang
consid
mode
transmiss
oral
hygien
gargl
togeth
hand
wash
mask
use
may
benefici
help
minimis
risk
communityand
hospitalacquir
respiratori
infect
gargl
also
deem
bring
favour
effect
remov
oralpharyng
proteas
help
viral
replic
effect
antisept
agent
kill
pathogen
paramount
select
garglesmouthwash
protect
hygien
achiev
ensur
antisept
agent
pass
standard
bactericid
virucid
activ
test
rapid
action
also
desir
length
time
individu
will
abl
keep
product
oral
caviti
limit
povidoneiodin
pvpi
broadspectrum
antimicrobi
use
infect
control
prevent
year
avail
variou
prepar
use
disinfect
skin
hand
mucos
surfac
well
wound
treatment
eye
applic
pvpi
wellestablish
gener
antimicrobi
activ
demonstr
vitro
efficaci
gramposit
gramneg
sporeform
bacteria
clostridia
bacillu
spp
mycobacteria
wide
rang
envelop
nonenvelop
virus
recent
vitro
studi
demonstr
rapid
virucid
activ
pvpi
product
ebola
viru
merscov
european
refer
envelop
viru
modifi
vaccinia
viru
ankara
mva
consid
proven
vitro
efficaci
gargl
pvpi
may
effect
method
prevent
spread
respiratori
virus
individu
contamin
airbornedroplet
rout
uptak
via
mouth
touch
mouth
food
contamin
hand
benefit
gargl
pvpi
alreadi
note
japanes
clinic
respiratori
guidelin
studi
investig
vitro
bactericid
virucid
efficaci
pvpi
garglemouthwash
relev
oral
respiratori
tract
pathogen
base
european
standard
antisept
product
test
pvpi
garglemouthwash
brandnam
isodin
manufactur
fukuchi
pharmaceut
co
ltd
japan
bactericid
test
mundipharma
pharmaceut
ltd
virucid
test
pvpi
solut
dilut
water
ml
ml
equival
concentr
activ
ingredi
prior
test
accord
manufactur
instruct
use
japan
use
cell
cultur
antisept
product
test
target
cell
often
sensit
activ
ingredi
overcom
test
product
test
dilut
solut
bactericid
test
correspond
concentr
pvpi
dilut
virucid
test
correspond
concentr
pvpi
gramposit
streptococcu
pneumonia
dsm
atcc
gramneg
klebsiella
pneumonia
dsm
refer
strain
test
inactiv
test
conduct
accord
suspens
test
organ
ad
product
test
solut
dirti
condit
gl
bovin
serum
albumin
bsa
mll
erythrocyt
interf
substanc
specifi
contact
time
aliquot
taken
bactericid
activ
portion
immedi
neutralis
tween
histidin
lecithin
sodium
thiosulph
test
suspens
two
sampl
spread
least
two
plate
number
surviv
test
organ
mixtur
calcul
sampl
reduct
factor
rf
determin
respect
correspond
test
suspens
reduct
bacteria
c
log
c
compar
control
consid
repres
effect
antibacteri
efficaci
accord
european
standard
inactiv
test
conduct
accord
viru
suspens
ad
product
test
solut
clean
gl
bsa
dirti
condit
gl
bsa
mll
erythrocyt
interf
substanc
except
rotaviru
suspens
test
without
protein
load
use
distil
water
interf
substanc
test
assay
compris
viru
suspens
interf
substanc
pvpi
product
defin
dilut
viru
control
mixtur
also
assess
use
distil
water
place
test
product
specifi
contact
time
sarscov
merscov
influenza
rotaviru
virucid
activ
solut
immedi
suppress
dilut
nine
volum
icecold
medium
mem
fc
serial
dilut
ten
fold
due
immedi
titrat
aftereffect
test
product
could
occur
test
suspens
six
well
well
sarscov
merscov
microtitr
plate
contain
confluent
monolay
host
cell
inocul
test
suspens
cell
incub
humidifi
atmospher
co
incub
medium
remov
stain
influenza
viru
rotaviru
infect
cell
fix
min
icecold
acetonemethanol
block
bsa
phosphatebuff
salin
pb
min
stain
immunoperoxidas
method
test
influenza
monoclon
antibodi
llwell
chemicon
temecula
ca
influenza
appli
incub
min
plate
wash
incub
secondari
horseradish
peroxidaselabel
antimous
antibodi
antimousehrp
dakocytom
germani
final
aec
substrat
sigma
st
loui
mo
usa
test
rotaviru
peroxidaselabel
polyclon
goat
antibodi
biotrend
germani
human
rotaviru
appli
incub
min
plate
wash
incub
secondari
horseradish
peroxidaselabel
antigoat
antibodi
sigmaaldrich
germani
dilut
final
aec
substrat
viru
test
aec
dilut
use
visualis
antibodi
bind
infect
cell
stain
red
stain
cell
examin
light
microscop
cell
examin
microscop
cytopath
effect
cpe
sar
mer
infect
cell
stain
examin
microscop
infect
cytopath
effect
viru
titr
determin
use
method
express
tissu
cultur
infecti
dose
tcid
ml
virucid
activ
determin
differ
logarithm
titr
viru
control
minu
logarithm
titr
test
viru
log
tcid
ml
differ
given
rf
includ
confid
interv
reduct
viru
titr
c
log
correspond
inactiv
c
regard
evid
suffici
virucid
activ
calcul
perform
accord
log
reduct
factor
produc
pvpi
garglemouthwash
defin
dilut
klebsiella
pneumonia
streptococcu
pneumonia
dirti
condit
shown
contact
time
tabl
bacteri
count
control
sampl
log
ml
klebsiella
pneumonia
log
ml
streptococcu
pneumonia
bacteri
count
reduc
log
ml
correspond
reduct
bacteri
count
c
contact
time
pvpi
concentr
dilut
ie
recommend
dilut
lower
concentr
reach
threshold
reduct
except
solut
streptococcu
pneumonia
log
reduct
factor
produc
pvpi
garglemouthwash
defin
dilut
test
viru
shown
interf
substanc
contact
time
tabl
viral
titr
present
control
sampl
clean
dirti
condit
respect
log
tcid
ml
sarscov
log
tcid
ml
merscov
log
tcid
ml
influenza
viru
subtyp
log
tcid
ml
rotaviru
clean
condit
viral
titr
reduc
log
tcid
ml
correspond
reduct
viral
titr
c
virus
test
contact
time
pvpi
gargl
concentr
ie
recommend
dilut
lower
pvpi
concentr
dilut
dilut
test
rotaviru
influenza
reach
log
reduct
viral
titr
c
except
concentr
influenza
clean
condit
oral
respiratori
tract
pathogen
repres
signific
threat
human
health
nosocomi
infect
widespread
especi
among
vulner
patient
import
contributor
morbid
mortal
grow
number
bacteri
infect
becom
harder
sometim
imposs
treat
antibiot
becom
less
effect
vaccin
respiratori
virus
either
exist
incomplet
coverag
emerg
infecti
diseas
outbreak
practic
appropri
hygien
recommend
healthcar
worker
individu
limit
spread
infect
break
transmiss
oral
hygien
could
improv
success
rate
hygien
measur
especi
respiratori
pathogen
data
vitro
studi
demonstr
rapid
bactericid
virucid
activ
pvpi
garglemouthwash
respiratori
pathogen
test
accord
european
standard
requir
minimum
contact
time
prove
suffici
pvpi
garglemouthwash
effect
recommend
dilut
japan
equival
concentr
activ
ingredi
pvpi
solut
shown
similar
rapid
antimicrobi
activ
previou
vitro
studi
bacteria
shimizu
et
al
demonstr
complet
efficaci
pvpi
solut
clinic
isol
klebsiella
pneumonia
serratia
marcescen
pseudomona
aeruginosa
alcaligen
faecali
alcaligen
xylosoxydan
within
use
simpl
methodolog
broth
turbid
method
anoth
studi
low
concentr
pvpi
garglemouthwash
kill
methicillinresist
staphylococcu
aureu
mrsa
pseudomona
aeruginosa
includ
multidrugresist
strain
within
presenc
oral
organ
matter
healthi
volunt
benzethonium
chlorid
bec
chlorhexidin
glucon
chg
ineffect
studi
compar
bactericid
activ
three
garglemouthwash
isol
standard
strain
gramposit
mrsa
neg
bacteria
pseudomona
aeruginosa
klebsiella
pneumonia
pvpi
dilut
elicit
rapid
kill
three
strain
exposur
cetylpyridinium
chlorid
cpc
effect
gramneg
strain
exposur
chg
ineffect
previou
virucid
studi
pvpi
gargl
found
inactiv
panel
virus
result
shown
bold
indic
bactericid
activ
c
log
reduct
factor
compar
control
dirti
condit
gl
bovin
serum
albumin
mll
erythrocyt
applic
pvpi
product
concentr
min
reduc
sarscov
viru
infect
tcid
ml
detect
level
studi
kariwa
et
al
although
shorter
contact
time
investig
ito
et
al
report
reduct
viral
infecti
titr
avian
influenza
virus
detect
limit
incub
six
differ
pvpi
product
includ
gargl
throat
spray
antiinfluenza
activ
pvpi
involv
inhibit
viral
haemagglutinin
bind
activ
viral
neuraminidas
catalyt
hydrolysi
present
studi
pvpi
oral
solut
concentr
also
effect
nonenvelop
rotaviru
without
interf
substanc
exposur
contrast
vitro
work
steinmann
et
al
pvpi
handwash
activ
nonenvelop
virus
test
sauerbrei
wutzler
pvpi
took
min
inactiv
polyomaviru
adenoviru
studi
virucid
bactericid
activ
pvpi
garglemouthwash
evalu
within
short
exposur
time
reflect
similar
shorter
time
actual
gargl
time
reallif
condit
sinc
length
time
individu
will
keep
antisept
product
oral
caviti
limit
pvpi
oral
solut
concentr
effect
pathogen
test
studi
minimum
contact
time
regardless
protein
load
except
rotaviru
test
without
protein
load
pathogen
erad
activ
moieti
non
pvpbound
free
iodin
releas
solut
pvpi
complex
penetr
cell
wall
inactiv
cell
form
complex
amino
acid
unsatur
fatti
acid
result
impair
protein
synthesi
alter
cell
membran
basic
mechan
action
lead
strong
microbicid
activ
express
multipl
mode
action
includ
disrupt
microbi
metabol
pathway
well
destabilis
structur
compon
cell
membran
caus
irrevers
damag
pathogen
result
studi
suggest
use
pvpi
garglemouthwash
may
use
protect
measur
oral
respiratori
tract
infect
inde
follow
swine
flu
outbreak
japan
ministri
health
labour
welfar
recommend
daili
gargl
protect
hygien
measur
prevent
upper
respiratori
tract
infect
urti
practic
support
find
studi
examin
role
gargl
healthi
individu
frequent
persist
urti
limit
clinic
studi
perform
use
pvpi
garglemouthwash
reduc
incid
respiratori
infect
differ
set
shiraishi
nakagawa
show
mean
reduct
rate
bacteri
count
immedi
gargl
pvpi
volunt
compar
chg
cpc
significantli
lower
absenc
rate
due
urti
japanes
middl
school
use
pvpi
gargl
encourag
compar
school
pvpi
gargl
use
patient
chronic
respiratori
diseas
gargl
pvpi
found
reduc
episod
infect
pseudomona
aeruginosa
staphylococcu
aureu
includ
mrsa
haemophilu
influenza
half
studi
prophylact
use
pvpi
gargl
patient
requir
intub
also
shown
signific
reduct
oropharyng
bacteri
count
oral
hygien
use
pvpi
may
particular
benefit
certain
patient
group
immunocompromis
patient
risk
prolong
viru
shed
increas
potenti
resist
antivir
drug
nosocomi
transmiss
patient
influenza
reduc
risk
secondari
bacteri
infect
may
appear
eg
otiti
media
children
thu
avoid
need
antibiot
possibl
hospitalis
patient
prevent
spread
influenza
high
season
safeti
profil
pvpi
well
establish
contrast
antisept
agent
pvpi
oral
care
product
lead
irrit
damag
oral
mucosa
even
prolong
use
although
measur
system
iodin
absorpt
may
occur
longterm
use
pvpi
clinic
manifest
thyroid
dysfunct
common
limit
work
clinic
relev
vitro
test
result
remain
unclear
need
support
investig
evalu
impact
gargl
pvpi
reallif
clinic
set
although
ethic
reason
clinic
studi
involv
highli
infect
danger
pathogen
may
feasibl
furthermor
test
limit
key
respiratori
microorgan
select
streptococcu
pneumonia
main
caus
communityacquir
pneumonia
mening
klebsiella
pneumonia
although
common
caus
respiratori
tract
infect
emerg
caus
multidrugresist
nosocomi
infect
addit
speci
repres
gramposit
neg
bacteria
although
studi
includ
common
bacteri
pathogen
caus
pneumonia
staphylococcu
aureu
pseudomona
aeruginosa
haemophilu
influenza
acinetobact
baumannii
efficaci
pvpi
pathogen
alreadi
demonstr
previou
studi
conclus
studi
result
taken
togeth
recommend
gargl
antisept
mouthwash
control
oral
respiratori
tract
infect
rapid
bactericid
virucid
efficaci
povidoneiodin
includ
pvpi
garglemouthwash
pathogen
caus
oral
respiratori
tract
infect
observ
vitro
vivo
studi
establish
safeti
profil
pvpi
year
use
provid
strong
rational
use
pvpi
oral
solut
protect
oropharyng
hygien
manag
individu
high
risk
exposur
oral
respiratori
pathogen
fund
sponsorship
studi
articl
process
charg
fund
mundipharma
research
gmbh
co
kg
mrg
author
full
access
data
studi
take
complet
respons
integr
data
accuraci
data
analysi
editori
assist
editori
assist
prepar
articl
provid
karen
mower
scientif
editori
fund
mrg
authorship
name
author
meet
intern
committe
medic
journal
editor
icmj
criteria
authorship
articl
take
respons
integr
work
whole
given
approv
version
publish
prior
present
work
present
annual
meet
japanes
societi
infect
prevent
control
japan
februari
disclosur
hygien
nord
gmbh
laboratori
ender
perform
studi
behalf
sponsor
mrg
maren
egger
paid
travel
expens
honorarium
mundipharma
pte
ltd
torsten
koburgerjanssen
employe
hygien
nord
gmbh
marku
eickmann
noth
disclos
juergen
zorn
employe
mrg
complianc
ethic
guidelin
articl
contain
studi
human
particip
anim
perform
author
open
access
articl
distribut
term
creativ
common
attributionnoncommerci
intern
licens
http
creativecommonsorglicens
permit
noncommerci
use
distribut
reproduct
medium
provid
give
appropri
credit
origin
author
sourc
provid
link
creativ
common
licens
indic
chang
made
